U.S., April 3 -- ClinicalTrials.gov registry received information related to the study (NCT06907173) titled 'Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)' on March 24.
Brief Summary: The goal of this clinical trial is to determine if treatment of patients with two doses of ketamine plus levetiracetam versus levetiracetam alone leads to more effective control of status epilepticus.
Study Start Date: Aug., 2025
Study Type: INTERVENTIONAL
Condition:
Status Epilepticus
Intervention:
DRUG: Levetiracetam (LEV) (60 mg/Kg) + 1 mg/kg Ketamine (KET)
The study drug will be produced at the central pharmacy, a GMP facility at the University of California, Davis. Diluted formulations are expected to remain s...